CLINICAL DATA COMPLETES ACQUISITION OF GENAISSANCE PHARMACEUTICALS

Clinical Data, Inc. (NASDAQ:CLDA) today announced that it has closed its previously announced acquisition of Genaissance Pharmaceuticals, Inc. following the approval of the merger by the stockholders of each of the two companies. The terms of the Agreement and Plan of Merger include the exchange of each outstanding share of Genaissance Pharmaceuticals common stock for 0.065 shares of Clinical Data common stock, and the exchange of Genaissance preferred shares for newly designated Clinical Data preferred shares.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1073937XSL_NEWSML_TO_NEWSML_WEB.xml)